Equities analysts forecast that Retrophin, Inc. (NASDAQ:RTRX) will report $36.71 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Retrophin’s earnings. The highest sales estimate is $37.22 million and the lowest is $36.20 million. Retrophin reported sales of $33.31 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 10.2%. The business is scheduled to issue its next quarterly earnings report on Thursday, August 3rd.

On average, analysts expect that Retrophin will report full year sales of $36.71 million for the current year, with estimates ranging from $150.50 million to $151.11 million. For the next year, analysts forecast that the firm will report sales of $184.40 million per share, with estimates ranging from $184.19 million to $184.60 million. Zacks’ sales calculations are an average based on a survey of research analysts that cover Retrophin.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.23. The business had revenue of $33.62 million for the quarter, compared to analyst estimates of $36.20 million. Retrophin had a negative net margin of 50.80% and a negative return on equity of 3.74%. The company’s revenue was up 15.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.14 EPS.

A number of research analysts have recently commented on RTRX shares. TheStreet upgraded shares of Retrophin from a “d” rating to a “c-” rating in a report on Friday, May 12th. Zacks Investment Research cut shares of Retrophin from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 3rd. William Blair restated an “outperform” rating on shares of Retrophin in a report on Thursday, April 6th. Finally, ValuEngine cut shares of Retrophin from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. Retrophin currently has an average rating of “Buy” and an average target price of $32.25.

Shares of Retrophin (RTRX) opened at 19.39 on Friday. The company’s market cap is $740.17 million. Retrophin has a one year low of $15.55 and a one year high of $24.57. The firm has a 50-day moving average of $17.87 and a 200-day moving average of $18.91.

WARNING: “Zacks: Analysts Expect Retrophin, Inc. (NASDAQ:RTRX) Will Post Quarterly Sales of $36.71 Million” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/01/zacks-analysts-expect-retrophin-inc-nasdaqrtrx-will-post-quarterly-sales-of-36-71-million.html.

Hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. raised its stake in Retrophin by 133.8% in the first quarter. Point72 Asset Management L.P. now owns 964,800 shares of the biopharmaceutical company’s stock worth $17,810,000 after buying an additional 552,065 shares during the period. Credit Suisse AG raised its stake in Retrophin by 8.4% in the first quarter. Credit Suisse AG now owns 57,025 shares of the biopharmaceutical company’s stock worth $1,052,000 after buying an additional 4,407 shares during the period. Tudor Investment Corp ET AL raised its stake in Retrophin by 19.5% in the first quarter. Tudor Investment Corp ET AL now owns 61,733 shares of the biopharmaceutical company’s stock worth $1,140,000 after buying an additional 10,067 shares during the period. Perceptive Advisors LLC raised its stake in Retrophin by 4.5% in the first quarter. Perceptive Advisors LLC now owns 2,807,525 shares of the biopharmaceutical company’s stock worth $51,826,000 after buying an additional 120,113 shares during the period. Finally, Bank of America Corp DE raised its stake in Retrophin by 102.4% in the first quarter. Bank of America Corp DE now owns 97,420 shares of the biopharmaceutical company’s stock worth $1,798,000 after buying an additional 49,277 shares during the period.

Retrophin Company Profile

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Get a free copy of the Zacks research report on Retrophin (RTRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.